Use

Apolipoprotein B (ApoB) is the predominant apoprotein attached to LDL, IDL, and VLDL particles. Elevated ApoB is associated with significantly increased cardiovascular disease risk—typically a 2–2.5-fold increase—and is supported by decades of scientific literature. It may offer more comprehensive risk assessment than LDL‑C alone and can guide statin therapy monitoring and broader CVD risk stratification, especially in patients with elevated triglycerides, diabetes, obesity, metabolic syndrome, or very low LDL‑C levels.